Nuformix plc announced on November 12, 2025, that the US Food and Drug Administration has requested further clarification for one specific element of the company's Orphan Drug Designation application for tranilast in idiopathic pulmonary fibrosis. The pharmaceutical development company initially submitted the ODD application in August 2025 for its NXP002 lead program, which aims to enable tranilast for inhaled delivery in treating IPF.
FDA Review Process Continues
As part of the standard ODD application process, the FDA can request additional information before making a final determination. Following Nuformix's response, the agency will issue either a designation confirmation letter, request more information, or deny the application. Dr. Dan Gooding, Executive Director of Nuformix, expressed confidence in the process, stating: "We will respond to FDA using the data we already have on file, having previously had a similar query from the EMA. I remain confident the process will reach a successful conclusion."
The company plans to submit its response as soon as possible using existing data and information already in its possession. Nuformix noted that it had previously addressed a similar query from the European Medicines Agency, suggesting the clarification request may involve comparable regulatory considerations.
Addressing Unmet Medical Need in IPF
Idiopathic pulmonary fibrosis represents a significant unmet medical need, characterized as a chronic lung disease with progressive tissue scarring that prevents proper lung function. According to the company's description, IPF is a progressive, fatal, age-associated lung disease affecting approximately three out of every 100,000 people in Europe. The condition typically presents in adults 65 or older and is usually fatal within two to five years after diagnosis.
Nuformix's approach involves drug repurposing, using its expertise in discovering, developing and patenting novel drug forms with improved physical properties. The company aims to develop new products in new indications that are differentiated from the original by way of dosage, delivery route or presentation, creating new commercial opportunities.
Business Development Activities Continue
Despite the pending FDA clarification, Nuformix continues to advance discussions with potential future licensing partners. The company indicated it will provide further updates as appropriate while awaiting the FDA's response to its clarification submission.
Successful Fundraising Initiative
Separately, Nuformix announced the successful completion of its underwritten Open Offer to Qualifying Shareholders, which closed on November 11, 2025. The offering received valid acceptances for 465,813,047 Open Offer Shares, representing approximately 408.5% take-up of the 114,040,535 shares available.
All qualifying shareholders who validly applied received their full Basic Entitlement, while applications under the Excess Application Facility were scaled back on a pro-rata basis. The company raised approximately £228,081 before expenses at the issue price of 0.2 pence per share. Following admission of the new shares, Nuformix's enlarged issued ordinary share capital will comprise 2,109,749,903 ordinary shares, with dealings expected to commence around 8:00 a.m. on November 13, 2025.
